Opioids And The Limits Of FDA Power
This article was originally published in The Pink Sheet Daily
FDA adds a MedGuide for immediate-release opioids and shrinks their indication; the products seemed destined for an educational REMS, but is there even more the agency could do?
You may also be interested in...
The US FDA commissioner also suggests the pain medications along with marijuana products should be regulated differently than other drugs.
Advisory committee to discuss data on abuse of Opana ER and generic oxymorphone extended-release and immediate-release products.
Former acting commissioner in line for the temporary position again under FDA policy, unless incoming Trump administration designates someone else.